1. Introduction {#sec1}
===============

The chemotherapeutic action of cisplatin (CP) and its analogues is based on the formation of Pt-DNA adducts, which leads to cell death.^[@ref1],[@ref2]^ CP with its transcription inhibition property suffers from undesirable side effects and drug resistance.^[@ref3],[@ref4]^ A chemotherapeutic drug is desired to fulfill the following criteria for its improved efficacy: (i) good selectivity between normal and cancer cells, (ii) localization inside cellular organelles such as mitochondria in preference to the nucleus to circumvent the nucleotide excision repair (NER) mechanism, and (iii) fluorescent property for cellular imaging to track the drug in vivo for understanding the mechanism of drug action from the in vitro studies. These requirements have necessitated design and development of new generation of drugs including those of transition metal-based.^[@ref5]−[@ref8]^ Iron is a natural choice as a substitute of platinum for its biocompatibility and based on the utility of bleomycins (BLMs) as iron-based anticancer agents.^[@ref9]−[@ref12]^ BLMs are glycopeptide antitumor antibiotics that cleave DNA in an oxidative manner.^[@ref12]−[@ref15]^ The structure of BLMs consists of three major domains having different functional roles with the chelation unit binding iron and activating molecular oxygen. Hertzberg and Dervan reported the model iron complex with the N-terminus domain and showed that methidiumpropyl-EDTA in the presence of ferrous ion and oxygen in an in situ reaction cleaves DNA in an oxidative manner generating radicals.^[@ref13]^

The present work stems from our interest to design iron-based photochemotherapeutic agents for in vivo applications. Photodynamic therapy (PDT) as a non-invasive therapeutic method is evolved with the combination of a photosensitizer (e.g., haematoporphyrin base), molecular oxygen, and visible light to generate cytotoxic reactive oxygen species (ROS).^[@ref16]−[@ref18]^ Borondipyrromethene (BODIPY) dyes as theranostics have excellent photophysical properties with different cores suitable for imaging and/or generating ROS on light activation.^[@ref19],[@ref20]^ By appending a BODIPY moiety on a drug molecule, one can also achieve organelle-specific targeting along with its bio-imaging property.^[@ref21],[@ref22]^

2. Results and Discussion {#sec2}
=========================

We have chosen BODIPY dyes as photosensitizers for generating ROS using low-energy visible light which has good tissue penetration power in the visible region.^[@ref23]^ Accordingly, we have designed, synthesized, and recently reported BODIPY-appended iron(III) catecholates, viz. \[Fe(L^1^/L^2^)(cat)Cl\] (L^1^ in **1**; L^2^ in **2**), of BODIPY-conjugated dipicolylamine (dpa) ligands L^1^ and L^2^ ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}).^[@ref24]^ The complexes reported to show significant in vitro PDT activity in infrared light with IC~50~ values of 12.5--19.5 μM with moderate dark toxicity in breast cancer MCF-7 cells and cervical HeLa cancer cells (λ = 600--720 nm, Waldmann PDT 1200 L). The complexes exhibited a ligand to metal charge transfer (LMCT) band within 675--790 nm and this spectral property was earlier used to study their in vitro photocytotoxicity in infrared light ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}).^[@ref25]^ Both the complexes were stable up to 48 h in 1% dimethyl sulfoxide (DMSO)--Dulbecco's phosphate-buffered saline (DPBS) of pH 7.2 in the dark. Imaging study with the highly fluorescent complex **1** showed its significant localization within the mitochondria with a moderate Pearson's coefficient value. Complex **2** displayed DNA-binding ability implying mitochondrial DNA (mt-DNA) as a possible target which lacks the NER mechanism. Both the complexes were able to generate singlet oxygen and hydroxyl radicals as the ROS, causing apoptotic cell death in the presence of light. Herein, we present the in vivo activity of complex **2** in the dark and infrared light (λ = 685 ± 10% nm, 20 mW/cm^2^, model BTL 4110 premium with 50 mW power) in luciferase-expressing human breast adenocarcinoma cells (BT474luc), following steps that are shown in [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}. In addition, the in vitro photocytotoxicity study on complex **2** was made in human breast adenocarcinoma BT474luc cells in infrared light of 600--720 nm (light dose: 30 J cm^--2^, Waldmann photoreactor) to have a better understanding of the in vivo and in vitro data.

![(a) Chemical structures of the pseudo-octahedral iron(III) catecholates with a FeN~3~O~2~Cl core having non-iodo (in complex **1**) and diiodo-BODIPY (in complex **2**) moieties. (b) UV--visible absorption spectra of the complexes **1** (green) and **2** (red) in DMSO. (c) LMCT band in the complexes **1** and **2** in DMSO.^[@ref24]^](ao-2018-01001e_0001){#fig1}

![Steps Involved in the Photochemotherapeutic Process in Vivo Using an Iron(III) Complex, \[Fe^III^(L^2^)(cat)Cl\] (**2**), Having Diiodo--BODIPY Moiety in L^2^, in Infrared Light of 685 nm](ao-2018-01001e_0006){#sch1}

Although several biocompatible metal complexes are known to act as potential candidates from the in vitro study, the reports on their in vivo activity are rare in the literature.^[@ref26]^ The photocytotoxicity of complex **2** in MCF-7 and HeLa cancer cells under infrared light irradiation has prompted us to study its anticancer potential in vitro and in vivo in BT474luc cancer cell line.^[@ref24]^ The anticancer activity of complex **2** was studied by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay (Figure S1, [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01001/suppl_file/ao8b01001_si_001.pdf)). The half-maximal inhibitory concentration (IC~50~) for complex **2** was 6 μM in BT474luc cancer cells in infrared light of 600--720 nm with relatively lower dark cytotoxicity (18 μM). The generation of ROS in BT474luc cells was evidenced from the 2,7-dichlorofluorescein diacetate (DCFDA) assay by recording the green fluorescence (λ~em~ = 525 nm, λ~ex~ = 488 nm) of 2′,7′-dichlorodihydrofluorescein (2,7-DCF), which is formed by the oxidation of hydrolyzed DCFDA ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}a). Cells were treated with complex **2** at its IC~50~ value of 6 μM followed by 4 h of post incubation and infrared light photo-irradiation. A substantial positive shift in the fluorescence was observed upon photo-irradiation of the BT474luc cancer cells with infrared light in the presence of the complex **2** in comparison to those kept in the dark. Cellular localization was studied in BT474luc cells to have an insight about the pharmacokinetics of the complexes. Complex **1** being green fluorescent (Φ~F~ = 0.1, λ~ex~ = 465 nm in DMSO) was chosen for the localization study in the cancer cells by confocal microscopy.

![(a) DCFDA assay for generation of ROS in BT474luc cells upon exposure to infrared light of 600--720 nm. (b) Confocal microscopic image of complex **1** (5 μM) showing its green emission in BT474luc cells on 4 h incubation in the dark and on merging with MitoTracker red and nuclear-staining dye DAPI displayed significant mitochondrial localization of the complex.](ao-2018-01001e_0002){#fig2}

The co-localization experiments were carried out using nucleus-specific blue-emitting dye 4′,6-diamidino-2-phenylindole (DAPI) and mitochondria-specific dye MitoTracker red with infrared emission. The cells were incubated with the fluorescent complex **1** (5 μM) at 37 °C for 4 h and then subjected to confocal imaging. The merged CLSM (confocal laser scanning microscopy) images showed that complex **1** was localized significantly in the mitochondria of the cells as evidenced from the yellow color in the merged image and Pearson's coefficient value of ∼0.6 ([Figures [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}b and S2, [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01001/suppl_file/ao8b01001_si_001.pdf)).^[@ref27]^ The results on BT474luc cells are in accordance to our earlier findings using HeLa and MCF-7 cells.^[@ref24]^

To study the cell death induced by complex **2** both under infrared light and dark, two sets of BT474luc cells were treated with 6 μM of the complex followed by 4 h incubation in the dark. One of the two sets were subjected to infrared light irradiation (λ = 600--720 nm, light dose: 30 J cm^--2^) and the other was kept in the dark following standard protocols. The assay was carried out after 16 h of post-incubation followed by treating with propidium iodide (PI) and Annexin-V FITC as trackers by flow cytometry. The red-emitting PI dye was used as a marker that intercalates with the DNA and stains only the necrotic cell population. Annexin-V, a calcium-dependent protein, binds to phosphatidylserine exposed on the outer surface of the cells because of membrane flipping in cells undergoing apoptosis. The double positive population has cells that are in late apoptosis with compromised cell membrane.

Complex **2** was observed to induce apoptosis in BT474luc cells both on irradiation with infrared light (600--720 nm) and on keeping in the dark ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}). About 95% of the cell population under irradiation with infrared light and ∼85% of the cell population under darkness were found to be in their apoptotic stage, whereas the population of cells in necrosis mode (stained with PI) was significantly low, which also suggests an overall apoptotic mode of cell death. The cell death in the dark mimics the anticancer activity of iron-BLMs, following a mechanistic pathway in which the Fe(III)--catecholate moiety with a redox active catechol unit having a redox potential of ∼0.4 V versus SCE (saturated calomel electrode) can generate radical species.^[@ref24]^ The enhancement of cellular death on light activation is related to the photo-Fenton effect in which light irradiation could potentially generate metal-mediated radical species involving the iron(III) catecholate moiety with a conversion to the reactive Fe(II)--semiquinone moiety, namely, Fe(III)--cat → Fe^II^--cat^•--^, on photo-activation of the LMCT band at ∼800 nm (H~2~cat, catechol).^[@ref28]^ The cat^•--^ can generate hydroxyl radicals as the ROS on reacting with molecular oxygen.

![FACS scan profiles of Annexin-V FITC and PI staining of BT474luc cells undergoing late apoptosis induced by complex **2** in infrared light (λ = 600--720 nm, light dose = 30 J cm^--2^) and in the dark. Top panels are cells untreated (left), cells + Annexin V-FTIC (middle), and cells + PI (right). Bottom panels are cells + Annexin V-FTIC + PI (left), cells + Annexin + PI + complex **2** in dark (D) (middle), and cells + Annexin + PI + complex **2** in light (L, 600--720 nm) (right).](ao-2018-01001e_0003){#fig3}

The in vivo anticancer activity of complex **2** against human breast adenocarcinoma (BT474 cell line) in nude mice was studied. About 10^6^ BT474luc cells were injected subcutaneously over the flank on each side of the mice. Tumor bearing mice were divided into two groups: a test group, which was treated with complex **2** at an optimized dose of 5 mg/kg body weight, and a control group. The mice were protected from light. For each mouse, one tumor was photo-irradiated with infrared light (685 nm ± 10%, 20 mW/cm^2^, BTL 4110 premium with 50 mW) 4 h after injection of complex **2** and the other tumor was protected from any light exposure. The tumors were monitored on a weekly basis by tumor diameter measurements and in vivo imaging for 15 days.

Fifteen days after the treatment, the tumor volume was found to be significantly lower in the light-treated group in comparison to the control group kept in the dark as can be seen from the in vivo imaging data ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}a). On the 15th day, the animals were sacrificed, and the tumors were photographed and weighed ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}b). Normalized photon flux of luciferase expressing tumor cells in control and treated groups clearly indicates that the treated group of complex **2** showed significant inhibitions in luciferase signal as compared to the control group ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}a). Tumor volume of mice measured over 15 days period since the treatments with complex **2** also showed significant inhibition of tumor growth in complex **2**-treated mice as compared to the control group ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}c). Consistent with the tumor volume and in vivo imaging results, tumor weight in the treated group showed a decrease in weight as compared to the control group where tumor weight had increased ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}b).

![(a) Representative in vivo imaging photographs of mice bearing tumors showing significant photochemotherapeutic effect of the redox active complex **2** with an {Fe^III^--cat}^+^ core which is susceptible to conversion to reactive {Fe^II^--cat^•--^}^+^ moiety for ROS generation on dioxygen activation. (b) Representative images of tumors after 15 days of treatment](ao-2018-01001e_0004){#fig4}

![(a) Normalized photon flux of luciferase-expressing BT474luc tumor cells in control and complex **2** treated groups over 15 days period after complex **2** treatment. (b) Tumor weight after 15 days of treatment with **2**. (c) Tumor volume measure of mice over 15 days period after treatment with **2** \[\**p* \< 0.05; \*\**p* \< 0.005\].](ao-2018-01001e_0005){#fig5}

Further, for 15 days, complex **2**-treated mice showed 100% survival, whereas the control group showed only 40% survival (Figure S3, [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01001/suppl_file/ao8b01001_si_001.pdf)) giving a clear indication that because of the anticancer activity of complex **2** the tumor growth was significantly suppressed in the complex-treated mice. Both the tumors were kept under light and darkness in case of complex-treated group showing inhibition of tumor, which are in agreement with the results from the DCFDA and Annexin assays indicating the chemotherapeutic effect of the redox active iron(III)--catecholate complex. However, there was no statistically significant inhibition in tumor growth for tumor treated with complex **2** in infrared light when compared to the one kept in the dark from the tumor volume and in vivo data. These results are contrary to our expectation and are in variance with the in vitro data. We speculate that because the compound is more activatable in green light than in infrared light, the effect of the light-treated animals might have been compromised. In any case, complex **2** showed a significant difference in the tumor growth compared to the untreated animals. In several recent studies, orthotopic and/or patient-derived xenograft (PDX) mouse models of cancer have been used to study the drug action in vivo. Orthotopic models involve the implantation of the tumor cells in an organ specific manner, which in case of breast cancer model being the fat pads. This model has advantage over the subcutaneous models in the sense, the tumors are in a natural breast environment and if one is studying the metastatic potential it is highly relevant model. On the other hand, the PDX nude mouse model helps to delineate the susceptibility of an individual tumor for a given chemotherapeutic molecule. This is highly useful for predicting response of the patient to a particular or combination of the drugs.^[@ref29],[@ref30]^ However, for the present in vivo experiment, subcutaneous xenograft mouse model was utilized by injecting luciferase-expressing BT474 cells in the flanks of the mice as the metastatic potential was not tested.

3. Conclusions {#sec3}
==============

In summary, the anticancer activity of iron(III) catecholates of dpa-conjugated BODIPY bases was studied under both in vitro and in vivo conditions using human breast adenocarcinoma BT474luc cells. The in vitro experiments showed predominant localization of the fluorescent complex **1** in the mitochondria of the cells. Complex **2** having the BODIPY moiety as a photosensitizer along with the {cat^2--^ → Fe(III)} LMCT band at ∼800 nm showed generation of cellular ROS on infrared light (600--720 nm) irradiation and induced apoptotic cell death. The results from the in vivo studies in the dark and infrared light indicated significant inhibition of tumor growth by complex **2** in human BT474luc cells with a minor enhancement of growth inhibition on infrared light exposure. The results are analyzed by invoking a photo-Fenton type mechanism, mimicking the chemotherapeutic action of iron-BLMs, in which the redox active iron(III)--catecholate unit could generate radicals via {Fe(II)--cat^•--^} moiety, while photo-activation of the infrared light LMCT band at ∼800 nm being responsible for its enhanced generation resulting additional growth inhibition. This work exemplifies an iron-based anticancer agent showing potential in vivo chemotherapeutic and photochemotherapeutic actions.

4. Experimental Section {#sec4}
=======================

4.1. Materials and Methods {#sec4.1}
--------------------------

MitoTracker red FM and DAPI were purchased from Invitrogen (USA). All other chemicals and reagents were obtained from S. D. Fine Chemicals (India) and Sigma-Aldrich (USA). Following the literature reports, the ligands and complexes were prepared.^[@ref24]^ UV--visible and emission spectra were obtained from Bruker Alpha and PerkinElmer Spectrum 750 spectrophotometers and a HORIBA Jobin Yvon IBH TCSPC fluorimeter (fitted with FluoroHub software analysis). The experiments conducted under infrared light irradiation were carried out with an infrared light photoreactor, Waldmann PDT 1200 L, and standard protocols. A TECAN microplate reader was used to record cytotoxicity data, and the data were plotted using GraphPad Prism 7 software. Flow cytometric experiments were carried out with Becton Dickinson fluorescent activated cell sorting (BD-FACS) Verse instrument (BD Biosciences) configured with a MoFLo XDP cell sorter and analyzer with three lasers (λ = 488, 365, and 640 nm) and ten-color parameters. A Windows 7 operating system with BD-FACS suite software for acquisition and analysis was employed for analyzing FACS data. Zeiss LSM 880 with an Airyscan confocal microscope was employed to record confocal microscopy images which are configured with an oil-immersion lens with magnification of 63×, and Zeiss software was used to process the images.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsomega.8b01001](http://pubs.acs.org/doi/abs/10.1021/acsomega.8b01001).Details of methods for in vitro and in vivo experiments; cytotoxicity data of complex **2**; scattered plots of complex **1** and the merged confocal image; and survival curve of mice over a period of 15 days ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01001/suppl_file/ao8b01001_si_001.pdf))
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BODIPY

:   1,3,5,7-tetramethyl-8-(4-pyridyl)-4,4′-difluorobora diazaindacene

BT474luc

:   luciferase-expressing human breast adenocarcinoma cells

CLSM

:   confocal laser scanning microscopy

DAPI

:   4′,6-diamidino-2-phenylindole

DCFDA

:   dichlorofluorescein diacetate
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:   dimethyl sulfoxide

DPBS

:   Dulbecco's phosphate-buffered saline

dpa

:   dipicolylamine

H~2~cat

:   catechol

HeLa

:   human cervical carcinoma cells
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:   ligand-to-metal charge transfer
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:   human breast cancer cells

MeOH
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mt-DNA

:   mitochondrial DNA

MTT

:   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
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:   nucleotide excision repair
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:   reactive oxygen species
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:   standard calomel electrode

UV--vis
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